Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.

CNS oncology - 1 Jan 2024

Yu Nina, Raslan Osama A, Lee Han Sung, Theeler Brett J, Raafat Tarek A, Fragoso Ruben, Shahlaie Kiarash, Aboud Orwa

Abstract excerpt

Craniopharyngiomas are tumors that arise from the remnants of Rathke's pouch along the nasopharynx to the diencephalon. Current standard of care includes maximal surgical resection versus adjuvant radiation if a maximal resection is unfeasible. Pharmacological therapy with MAPK targeted agents is an emerging therapeutic option for tumors with BRAF V600E mutations. We report a 45-year-old male with a strictly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Craniopharyngioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Piperidines

Share to Pituitary Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 38348829
DOI: 10.2217/cns-2023-0018
PMCID: PMC11131344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.PMID 38348829Read ↗

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Semantic proximity Read ↗

[Molecularly Targeted Therapy for Craniopharyngioma].Semantic proximity Read ↗

Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.Semantic proximity Read ↗

BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.Semantic proximity Read ↗

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsSemantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.Semantic proximity Read ↗

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngiomaSemantic proximity Read ↗

BRAF plus MEK inhibition effective in papillary craniopharyngioma.Semantic proximity Read ↗

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.Semantic proximity Read ↗

Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.Semantic proximity Read ↗

Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.